Oncology Corporate Profile
Telormedix ( www.telormedix.com ), founded in October 2007, is a biopharmaceutical company focused on targeted immunity and modulation of the innate immune system for treating cancer and inflammatory diseases. The Company's lead product, Vesimune (TMX-101), has just successfully completed a Phase II clinical trial for the treatment of CIS (carcinoma in situ) of the bladder. In addition, Telormedix is developing two additional TLR7-targeted molecules, TMX-201 and TMX-202 both of which would make good vaccine adjuvants. As these molecules have substantially improved pharmacokinetics and pharmacodynamics profiles they have the potential to fully realise the anticancer promise of TLR 7 agonists. One of these molecules, TMX-202 has recently been selected for preclinical study for the topical treatment of skin cancers and other indications. The candidate has already successfully completed a number of in vivo studies.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|TMX-101||toll-like receptor 7 (TLR7)||Bladder cancer||II|
|TMX-202||toll-like receptor 7 (TLR7)||Various cancer types||Preclinical|
|TMX-201||toll-like receptor 7 (TLR7)||Various cancer types||Preclinical|
View additional information on product candidates here »